Advanced Life Sciences' Cethromycin For CAP Cleared For FDA Submission
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Firm plans third quarter NDA for mild-to-moderate community-acquired pneumonia indication. ALS CEO says the filing milestone will help with its search for a partner